article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., New systemic agents and even new concepts in the prevention of atopic dermatitis and the microbiome seem just around the corner too, Dr. Lio says. “We Food and Drug Administration (FDA) recently OKed a label update for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc.,

article thumbnail

JNJ Continues to Grow AD Pipeline With New Licensing Agreement

The Dermatology Digest

Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical.

article thumbnail

There’s Something About Eblasakimab: Aslan, Zenyaku Partner to Investigate How it Differs From Other Biologics for AD

The Dermatology Digest

Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD).

article thumbnail

Off-label Pearl: Exploring the Role of Narrowband UVB Phototherapy Plus Oral JAK Inhibitors in Vitiligo

The Dermatology Digest

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Topical isotretinoin, even when covering 90% of a patient’s body surface area, showed minimal systemic absorption. Watch Now The Lowdown on Molluscum Nanette B. Watch Now Biosimilars in Dermatology: Where Do They Fit in?

article thumbnail

Case 2: Female, 15 Years Old

Dermatology Times

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options.

article thumbnail

Label Update: FDA Green Lights Dupilumab for AD Patients With Moderate-to-Severe Hand and Foot Involvement

The Dermatology Digest

Food and Drug Administration (FDA) has updated the label for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. and Sanofi report. “We

article thumbnail

Breaking News: Japan First in the World to Approve Dupilumab for CSU

The Dermatology Digest

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) and Novartis Pharmaceuticals). Japan is the first country to approve dupilumab for CSU. This study met the primary and all key secondary endpoints.